LENZ Therapeutics, Inc. (LENZ)

USD 29.52

(2.22%)

Market Cap (In USD)

813.11 Million

Revenue (In USD)

-

Net Income (In USD)

-124.65 Million

Avg. Volume

224.51 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.266-38.93
PE
-12.62
EPS
-2.34
Beta Value
0.0
ISIN
US52635N1037
CUSIP
-
CIK
-
Shares
27544500.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Evert B. Schimmelpennink
Employee Count
-
Website
-
Ipo Date
2024-03-22
Details
LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.